Extramedullary disease of multiple myeloma (EM) remains a treatment challenge even in the era of new drugs. While many reports analyzing various aspects of EM have been published, mechanism of EM development has not been clarified yet. This review summarizes current knowledge about this clinical entity, including its history, diagnostics, imaging methods, incidence, prognosis, current treatment options, risk factors and known molecular mechanisms that might be involved in pathogenesis of EM.

Babak Myeloma Group Department of Pathological Physiology Faculty of Medicine Masaryk University Brno Czech Republic

Department of Hemato Oncology University Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc Olomouc Czech Republic

Department of Hematooncology University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Brno Czech Republic

References provided by Crossref.org

MicroRNA Profiling of Bone Marrow Plasma Extracellular Vesicles in Multiple Myeloma, Extramedullary Disease, and Plasma Cell Leukemia

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease

Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients

Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors

Involvement of Small Non-Coding RNA and Cell Antigens in Pathogenesis of Extramedullary Multiple Myeloma

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas

Identification of patients at high risk of secondary extramedullary multiple myeloma development

Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

A rare case of bifocal, extramedullary and hyposecretory relapse of multiple myeloma

Natural Killer Cells in the Malignant Niche of Multiple Myeloma